EMA CHMP issued a positive opinion on the safety of Filgotinib, a selective JAK1 inhibitor, based on testicular safety data from the MANTA & MANTA-RAy studies. Gilead withdrew filgotinib from US market w/ FDA concerns on testicular safety in 12/20 https://t.co/EawqOGZEZe https://t.co/Bcp6rOReCR

NEJM: 70 yoWM w/ 3-wk temporal headaches, jaw pain with chewing, temporal artery tender and thickened, but NO vision Sxs. a 15, CRP 24 mg/L. and Doppler US showed “halo sign” . Temp art Bx confirmed the Dx of GCA https://t.co/mIUA8pMh2l https://t.co/o50MkidinC

J Rheum review shows 4,444 rheums in 2015 & 3,547 in 2020 recv some sort of pharma payments (There are ~5000 US Rheums). Pandemic drops affected travel, etc (98%), speaking (72%), meals (72%), but less consulting (23%) https://t.co/2UMqp4XDhJ https://t.co/dHtHUBO1Wk

Downstream revenues from Rheum? The Rheumatologist reports and impt reference showing for every $1 dollar office visit billed, $12.14 generated in downstream revenues (infusions, labs, surgery). Cognitive specialists are undervalued! https://t.co/YatkwrBCeQ https://t.co/OzSsxXKVhC

Review of risk factors for osteoporosis and fractures in #RA. OP Risk factors same as gen population (but more prevalent in RA) - smoking, calcium intake, vit D deficiency, hypogonadism and chronic exposure to glucocorticoids https://t.co/KsE5ag29ZN https://t.co/OQtfoKcIX2

Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day after MTX. (based on AIA was induced in female Lewis rats) https://t.co/gBWhjhS8Nu https://t.co/5799lleK22

Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/Rais8fKame https://t.co/F3B9W7u7VO

No Special Heart Risk With JAK Inhibitors, Study Finds Patients taking JAK inhibitors for RA experienced similar cardiovascular outcomes as those using the TNF blocker adalimumab (Humira), analysis of French national registry data indicated. https://t.co/oUt1hz88ll https://t.co/RkUUvfC4YK

Arthritis Clinical Trials Comparison Grid https://t.co/rLxTauJqX1 https://t.co/U7i5baSNwt

Sjogrens - Dx tips, myths & mistakes: • SS not rare; affects 1 in 400 • 95% female, but SS is more severe in men • African Americans have a severe systemic phenotype • Asians report dryness Sxs • Smoking & alcohol intake often avoided by SS pts https://t.co/B2hR7z8H5Z https://t.co/g0FKhcmoXa

Actual video of needle arthroscopy in patients w/ suspected septic arthritis. https://t.co/tWgP4ZpFBJ https://t.co/cLWM48NBlA

Biomedical researchers are at their most creative/innovative EARLY in their career. Study based on 5.6 million papers (1980 to 2009). While least innovative drop out early; in the remaining, innovativeness tends to decline over their career.https://t.co/XY5xQfY8Ba https://t.co/Cs3MUr7qIi